文献速递临床试验与 GCP医学人工智能与信息学

虚拟多交叉随机对照试验评估哌甲酯治疗轻度认知障碍可行性的先导方案

A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment.
PubMed 文献 · Trials · 2020-12-11

针对阿尔茨海默病及相关痴呆,传统平行组试验成本高且难以在异质患者中检出效应;

要点

  • MCRCT设计使每例患者作为自身对照,可在个体水平无偏评估疗效。
  • 研究完全虚拟开展,仅设可选现场筛查访视,评估可行性与保留率。
  • 探索性结局包括神经心理评估、每日脑力游戏、活动记录及神经精神功能评估。

核心结论

  • 本先导研究将评估在早期AD/ADRDs中开展虚拟MCRCT symptomatic治疗的可行性。

研究设计与样本

  • 试验流程为4周导入期后3个月长治疗区块,每区块含2周哌甲酯与2周安慰剂随机顺序。
  • 试验完全虚拟开展,仅设可选现场筛查访视;注册号NCT03811847,2019年1月21日注册。

主要发现

  • 主要结局为可行性,以依从性和保留率衡量。
  • 次要及探索性结局包括每个治疗期结束时的神经心理评估、研究期间每日脑力游戏、活动记录、神经精神与功能评估。

临床怎么用

  • 为AD/ADRDs症状治疗试验提供更高效的设计参考,并比较家庭每日脑力游戏与标准神经心理测量。
  • 关注依从性、药物耐受性、参与度、学习效应、各区块每日测量趋势与稳定性、药物携带效应及标准与简短每日评估的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The conventional clinical trial design in Alzheimer's disease (AD) and AD-related disorders (ADRDs) is the parallel-group randomized controlled trial. However, in heterogeneous disorders like AD/ADRDs, this design requires large sample sizes to detect meaningful effects in an "average" patient. They are very costly and, despite many attempts, have not yielded new treatments for many years. An alternative, the multi-crossover, randomized control trial (MCRCT) is a design in which each patient serves as their own control across successive, randomized blocks of active treatment and placebo. This design overcomes many limitations of parallel-group trials, yielding an unbiased assessment of treatment effect at the individual level ("N-of-1") regardless of unique patient characteristics. The goal of the present study is to pilot a MCRCT of a potential symptomatic treatment, methylphenidate, for mild-stage AD/ADRDs, testing feasibility and compliance of participants in this design and efficacy of the drug using both standard and novel outcome measures suited for this design. METHODS: Ten participants with mild cognitive impairment or mild-stage dementia due to AD/ADRDs will undergo a 4-week lead-in period followed by three, month-long treatment blocks (2 weeks of treatment with methylphenidate, 2 weeks placebo in random order). This trial will be conducted entirely virtually with an optional in-person screening visit. The primary outcome of interest is feasibility as measured by compliance and retention, with secondary and exploratory outcomes including cognition as measured by neuropsychological assessment at the end of each treatment period and daily brain games played throughout the study, actigraphy, and neuropsychiatric and functional assessments. DISCUSSION: This pilot study will gauge the feasibility of conducting a virtual MCRCT for symptomatic treatment in early AD/ADRD. It will also compare home-based daily brain games with standard neuropsychological measures within a clinical trial for AD/ADRD. Particular attention will be paid to compliance, tolerability of drug and participation, learning effects, trends and stability of daily measures across blocks, medication carryover effects, and correlations between standard and brief daily assessments. These data will provide guidance for more efficient trial design and the use of potentially more robust, ecological outcome measures in AD/ADRD research. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03811847 . Registered on 21 January 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. DesRuisseaux LA, Williams VJ, McManus AJ, et al. A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment. Trials. 2020. PMID: 33308285. doi:10.1186/s13063-020-04752-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。